RELMADA THERAPEUTICS, INC.
Relmada Therapeutics is a publicly traded, clinical-stage biotechnology company developing drug candidates for cancer, neurological disorders and other diseases. Its lead candidate, NDV-01, is a controlled-release intravesical formulation of gemcitabine and docetaxel for non-muscle-invasive bladder cancer. It is in a Phase 2 clinical trial and is being developed for high-risk, BCG-unresponsive and intermediate-risk disease. Relmada’s second candidate, sepranolone, is a neurosteroid being developed for Prader-Willi syndrome, Tourette Syndrome, essential tremor and other conditions related to excessive GABAergic activity. Relmada acquires and licenses development candidates, then advances them through clinical development; it has no approved products or commercial products. Its development programs include NDV-01, licensed from Trigone Pharma, and sepranolone, acquired from Asarina Pharma. The company is headquartered in Coral Gables, Florida.
No enriched coverage for $RLMD in the last 7 days.
No SEC Form 4 filings for $RLMD in the last 30 days.
See all $RLMD insider activity →Relmada Therapeutics (RLMD) executives bought shares at $4.10-$4.25. PVH (PVH) CEO bought $1M in stock. Clipper Realty (CLPR) director bought $388K in shares. Gloo (GLOO) chair bought 50,000 shares. Hagerty (HGTY) sold $122M in shares. Dell (DELL) saw $55M in sales by Silver Lake. Hinge Health (HNGE) CEO sold $22.3M in shares.
Relmada Therapeutics Inc. (RLMD) stock rose 12.28% following positive clinical trial news and insider buying by CEO and CFO. The company has no revenue but a strong balance sheet with $218M in cash and no debt. Analysts note a nascent uptrend with support at $4.10 and resistance at $5.00-$5.25. The stock is up from $4.09 to $4.57 on strong volume.
Shenouda Maged (Chief Financial Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.22 ($4.20–$4.25, $0.84M total) across 2 trades over 2026-09-09 to 2026-09-10.
Recent RLMD coverage spans financial news, insider activity and earnings.
Insider buying may support short‑term price upside.
The insider buying signals confidence and provides short‑term upside momentum.
Insider buying by a senior executive may signal confidence, but the amount is modest relative to market cap.
Insider purchase signals confidence from management, modestly bullish for RLMD.
Execution-focused update with explicit IND timing and a longer cash runway, likely supporting near-term risk appetite but keeping biotech binary risk elevated.
AlphAI scores every news story that mentions RLMD with an AI model for sentiment and relevance, and aggregates insider trades from RELMADA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Relmada Therapeutics (RLMD) executives bought shares at $4.10-$4.25. PVH (PVH) CEO bought $1M in stock. Clipper Realty (CLPR) director bought $388K in shares. Gloo (GLOO) chair bought 50,000 shares. Hagerty (HGTY) sold $122M in shares. Dell (DELL) saw $55M in sales by Silver Lake. Hinge Health (HNGE) CEO sold $22.3M in shares.
2 min readRelmada Therapeutics Inc. (RLMD) stock rose 12.28% following positive clinical trial news and insider buying by CEO and CFO. The company has no revenue but a strong balance sheet with $218M in cash and no debt. Analysts note a nascent uptrend with support at $4.10 and resistance at $5.00-$5.25. The stock is up from $4.09 to $4.57 on strong volume.
2 min readShenouda Maged (Chief Financial Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.22 ($4.20–$4.25, $0.84M total) across 2 trades over 2026-09-09 to 2026-09-10.
1 min readTRAVERSA SERGIO (Chief Executive Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.14 ($4.10–$4.18, $0.83M total) across 2 trades over 2026-09-09 to 2026-09-10.
1 min readRelmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.
6 min readRELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational
6 min readRelmada Therapeutics (NASDAQ:RLMD) reported Q1 2026 results on May 12, citing positive 12-month Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, with a 95% complete response rate, according to the company. It said it has $234 million cash and a $160 million financing, expected to fund operations through 2029, including a Phase 3 RESCUE program starting mid-2026.
3 min readMarketBeat compared Relmada Therapeutics (NASDAQ:RLMD) and Clearmind Medicine (NASDAQ:CMND). RLMD has a consensus target price of $12.00 (67.95% upside) versus CMND’s lower outlook, and RLMD is trading at a lower P/E. Institutional ownership is 45.2% for RLMD and 96.1% for CMND; beta is 0.43 for RLMD and 0.87 for CMND.
4 min readRelmada Therapeutics announced strong 12-month Phase 2 data for NDV-01 in bladder cancer, with complete response rates up to 95% and durable responses up to 80% at 12 months. The company plans to launch its Phase 3 RESCUE program in mid-2026 and has secured $234 million in funding, ensuring operations through 2029 despite increased quarterly net losses. An analyst has rated RLMD stock as a Buy with a $19.00 price target.
3 min readLeerink Partners has upgraded Relmada Therapeutics (RLMD) from Market Perform to Outperform, with an average one-year price target of $10.20 per share, suggesting a 160.54% upside. Institutional ownership in RLMD increased by 49.27% in the last quarter, and the put/call ratio indicates a bullish outlook for the company.
3 min read
